Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Mar;52(4):1249-1256.
doi: 10.1007/s00259-024-06980-8. Epub 2024 Nov 14.

Comparison of clinical performance between late and standard total-body [68 Ga]Ga-PSMA-11 in biochemical recurrent prostate cancer

Qiaochu Chen #  1 , Liang Dong #  2 , Lian Xu  1 , Haitao Zhao  1 , Lianghua Li  1 , Gang Huang  3   4 , Jianjun Liu  5 , Ruohua Chen  6   7
Affiliations
Comparative Study

Comparison of clinical performance between late and standard total-body [68 Ga]Ga-PSMA-11 in biochemical recurrent prostate cancer

Qiaochu Chen et al. Eur J Nucl Med Mol Imaging. 2025 Mar.

Abstract

Background and purpose: Enhanced lesion detection in prostate cancer is observed with late [68 Ga]Ga-PSMA-11 PET/CT imaging compared to standard [68 Ga]Ga-PSMA-11 PET/CT imaging (50-100 min p.i.). However, the poor image quality of late imaging using short axial field of view (SAFOV) PET/CT has hindered its sole clinical adoption. Conversely, the image quality of late imaging with a long axial field of view (LAFOV) [68 Ga]Ga-PSMA-11 PET/CT fulfills clinical diagnostic requirements. Nonetheless, the diagnostic efficacy of late LAFOV [68 Ga]Ga-PSMA-11 PET/CT with forced diuresis and its impact on treatment decisions, compared to standard LAFOV [68 Ga]Ga-PSMA-11 PET/CT, remains unclear. This study aims to compare the rate of PET positivity between late and standard LAFOV [68 Ga]Ga-PSMA-11 PET/CT and to evaluate the influence of late LAFOV [68 Ga]Ga-PSMA-11 PET/CT with forced diuresis on treatment decisions relative to standard scans.

Methods: From January 2021 to April 2024, 127 patients with biochemical recurrence of prostate cancer post-radical prostatectomy were enrolled to undergo both standard and late LAFOV [68 Ga]Ga-PSMA-11 PET/CT scans at Shanghai Renji Hospital. We compared the rate of PET positivity between the two modalities at the patient level and across different anatomical regions. We assessed the added diagnostic value of late LAFOV [68 Ga]Ga-PSMA-11 PET/CT and its impact on modifying patient treatment plans.

Results: The image quality of late LAFOV [68 Ga]Ga-PSMA-11 PET/CT with forced diuresis in all patients met clinical diagnostic requirements. The rate of PET positivity of late LAFOV [68 Ga]Ga-PSMA-11 PET/CT with forced diuresis were significantly higher than those of standard LAFOV [68 Ga]Ga-PSMA-11 PET/CT (80.31% [102/127] vs. 65.35% [83/127]; P < 0.001). Late LAFOV [68 Ga]Ga-PSMA-11 PET/CT demonstrated higher lesion SUVmax (16.69 ± 16.42 vs. 11.91 ± 10.72, P < 0.001) and TBR (6.26 ± 7.21 vs. 3.44 ± 3.57, P < 0.001) compared to standard LAFOV scans. Additionally, 14.17% (18/127) of patients experienced changes in their treatment regimen due to the superior detection capabilities of late LAFOV [68 Ga]Ga-PSMA-11 PET/CT with forced diuresis compared to the standard scan.

Conclusions: The rate of PET positivity of late LAFOV [68 Ga]Ga-PSMA-11 PET/CT with forced diuresis compared to standard LAFOV [68 Ga]Ga-PSMA-11 PET/CT highlight its potential as a valuable diagnostic tool for biochemically recurrent prostate cancer. This study paves the way for using late LAFOV [68 Ga]Ga-PSMA-11 PET/CT with forced diuresis for prostate cancer imaging in daily clinical practice, facilitating more accurate and timely diagnoses.

Keywords: 11 PET/CT; Biochemical Recurrent Prostate Cancer; Late LAFOV [68 Ga]Ga; PSMA; Standard LAFOV [68 Ga]Ga; The rate of PET positivity.

PubMed Disclaimer

Conflict of interest statement

Declarations. Consent for publication: Not applicable. Ethical approval: The study involving human participants obtained ethical clearance and adhered to the ethical principles outlined by the ethics committee at Renji Hospital and the Declaration of Helsinki of 1964. This research did not involve animal subjects. Consent to participate: All participants provided informed consent prior to undergoing the examination procedures. Disclosure: No potential conflict of interest was reported.

Similar articles

See all similar articles

Cited by

References

    1. Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N. Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016;70:926–37. - DOI - PubMed
    1. Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schoder H, Wan S, Wester HJ, Hope TA, Herrmann K. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466–86. - DOI - PubMed - PMC
    1. Alberts I, Niklas-Hunermund J, Sachpekidis C, Zacho HD, Mingels C, Dijkstra L, Bohn KP, Lappchen T, Gourni E, Rominger A, Afshar-Oromieh A. Combination of Forced Diuresis with Additional Late Imaging in (68)Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake. J Nucl Med. 2021;62:1252–7. - DOI - PubMed
    1. Unterrainer LM, Ruchalski K, Allen-Auerbach MS, Calais J, Benz MR. PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have? J Nucl Med. 2024;65(5):818–9. - DOI - PubMed
    1. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95. - DOI - PubMed

Publication types

LinkOut - more resources